Logo image of FULC

FULCRUM THERAPEUTICS INC (FULC) Stock Fundamental Analysis

NASDAQ:FULC - Nasdaq - US3596161097 - Common Stock - Currency: USD

7.82  -0.09 (-1.14%)

After market: 7.82 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to FULC. FULC was compared to 194 industry peers in the Pharmaceuticals industry. FULC has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, FULC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FULC had negative earnings in the past year.
In the past year FULC has reported a negative cash flow from operations.
In the past 5 years FULC always reported negative net income.
FULC had a negative operating cash flow in each of the past 5 years.
FULC Yearly Net Income VS EBIT VS OCF VS FCFFULC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

FULC has a Return On Assets of -3.73%. This is in the better half of the industry: FULC outperforms 77.84% of its industry peers.
With an excellent Return On Equity value of -4.00%, FULC belongs to the best of the industry, outperforming 80.93% of the companies in the same industry.
Industry RankSector Rank
ROA -3.73%
ROE -4%
ROIC N/A
ROA(3y)-29.99%
ROA(5y)-35.8%
ROE(3y)-33.54%
ROE(5y)-42.65%
ROIC(3y)N/A
ROIC(5y)N/A
FULC Yearly ROA, ROE, ROICFULC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FULC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FULC Yearly Profit, Operating, Gross MarginsFULC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

9

2. Health

2.1 Basic Checks

FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FULC has less shares outstanding
The number of shares outstanding for FULC has been increased compared to 5 years ago.
There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FULC Yearly Shares OutstandingFULC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
FULC Yearly Total Debt VS Total AssetsFULC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 12.85 indicates that FULC is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 12.85, FULC belongs to the best of the industry, outperforming 87.63% of the companies in the same industry.
There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.85
ROIC/WACCN/A
WACC10.12%
FULC Yearly LT Debt VS Equity VS FCFFULC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

FULC has a Current Ratio of 22.63. This indicates that FULC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 22.63, FULC belongs to the best of the industry, outperforming 91.75% of the companies in the same industry.
FULC has a Quick Ratio of 22.63. This indicates that FULC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 22.63, FULC belongs to the best of the industry, outperforming 91.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.63
Quick Ratio 22.63
FULC Yearly Current Assets VS Current LiabilitesFULC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.63% over the past year.
The Revenue has grown by 2752.05% in the past year. This is a very strong growth!
The Revenue has been growing by 61.03% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)95.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.88%
Revenue 1Y (TTM)2752.05%
Revenue growth 3Y61.03%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

FULC is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.32% yearly.
Based on estimates for the next years, FULC will show a very negative growth in Revenue. The Revenue will decrease by -15.40% on average per year.
EPS Next Y-441.79%
EPS Next 2Y-136.49%
EPS Next 3Y-66.05%
EPS Next 5Y-29.32%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-15.4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
FULC Yearly Revenue VS EstimatesFULC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2028 2029 2030 2031 2032 50M 100M 150M 200M
FULC Yearly EPS VS EstimatesFULC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FULC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FULC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FULC Price Earnings VS Forward Price EarningsFULC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FULC Per share dataFULC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A cheap valuation may be justified as FULC's earnings are expected to decrease with -66.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-136.49%
EPS Next 3Y-66.05%

More info and screens

0

5. Dividend

5.1 Amount

FULC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FULCRUM THERAPEUTICS INC

NASDAQ:FULC (7/24/2025, 8:00:00 PM)

After market: 7.82 0 (0%)

7.82

-0.09 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners95.91%
Inst Owner Change0%
Ins Owners0.63%
Ins Owner Change-0.01%
Market Cap422.12M
Analysts78.46
Price Target8.31 (6.27%)
Short Float %10.64%
Short Ratio8.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.42%
Min EPS beat(2)5.45%
Max EPS beat(2)15.39%
EPS beat(4)4
Avg EPS beat(4)1737%
Min EPS beat(4)3.64%
Max EPS beat(4)6923.53%
EPS beat(8)8
Avg EPS beat(8)874.49%
EPS beat(12)9
Avg EPS beat(12)582.58%
EPS beat(16)13
Avg EPS beat(16)440.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.55%
PT rev (3m)43.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.59%
EPS NY rev (3m)2.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.28
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)-0.07
EYN/A
EPS(NY)-1.23
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS1.48
BVpS4.5
TBVpS4.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.73%
ROE -4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.99%
ROA(5y)-35.8%
ROE(3y)-33.54%
ROE(5y)-42.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.45%
Cap/Sales 0.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.63
Quick Ratio 22.63
Altman-Z 12.85
F-Score6
WACC10.12%
ROIC/WACCN/A
Cap/Depr(3y)40.72%
Cap/Depr(5y)49.27%
Cap/Sales(3y)16.46%
Cap/Sales(5y)14.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.88%
EPS Next Y-441.79%
EPS Next 2Y-136.49%
EPS Next 3Y-66.05%
EPS Next 5Y-29.32%
Revenue 1Y (TTM)2752.05%
Revenue growth 3Y61.03%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-15.4%
EBIT growth 1Y82.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-242.11%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y97.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.56%
OCF growth 3YN/A
OCF growth 5YN/A